Iovance Biotherapeutics (IOVA) rises 35.02% intraday after Q2 earnings beat and FDA Fast Track designation
ByAinvest Wire
Thursday, Aug 6, 2026 9:49 am ET1min read
IOVA--
Iovance Biotherapeutics (IOVA) shares rose 35.02% in intraday trading after the company reported Q2 2026 earnings that beat estimates, with total product revenue rising 66% year over year to approximately $99.3 million. The biotech firm also announced it is reviewing its full-year 2026 revenue guidance upward and received FDA Fast Track Designation for lifileucel in soft tissue sarcomas.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
LEGAL
Privacy PolicyTerms of UseAIME Terms of UseBrokerage DisclaimerAI Risk DisclosuresEditorial PolicyCONTACT US
Email: support@ainvest.com, editorial@ainvest.com, corrections@ainvest.com, press@ainvest.com, legal@ainvest.com
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet